Electrical Storm and Polymorphic VT/VF

The sequence begins with a single episode of VT. In a patient with an ICD (an implantable cardioverter-defibrillator, covered in Volume X, Chapter 3), the device detects the arrhythmia and delivers a shock. That shock hurts. It causes severe pain, anxiety, and a massive surge of catecholamines from the adrenal glands and sympathetic nerve terminals.

Catecholamines act directly on ventricular myocytes. They increase intracellular calcium loading, shorten the refractory period, enhance automaticity, and lower the threshold for reentry. In scar tissue, catecholamines can alter conduction velocity through surviving fiber bundles, making it easier for a wavefront to find the excitable gap and sustain a circuit.

The result: another episode of VT. Another shock. Another catecholamine surge. Each cycle feeds the next. The intervals between episodes shorten. Some patients receive dozens of shocks in a single hour.

Breaking this loop is the central therapeutic goal. Every drug, every procedure, every decision in electrical storm management maps onto a specific node in this cycle.

When the storm consists of a single, repeating VT morphology, the mechanism is almost always scar-related reentry. The patient has a fixed substrate: a myocardial infarction scar, a dilated cardiomyopathy with fibrosis, or a healed surgical incision. Within that scar sits a channel of surviving myocytes. Under the right conditions, a wavefront enters one end, crawls through, and exits the other end to find excitable tissue waiting. The circuit fires again. And again.

What turns a single episode into a storm is the sympathetic amplification we just described. Catecholamines widen the excitable gap in the reentrant isthmus, making the circuit more robust. They also increase the rate of spontaneous PVCs that can reinitiate the circuit after each termination.

Acute management targets every level of the problem simultaneously.

IV amiodarone is the first-line antiarrhythmic. It prolongs refractoriness in the scar channel, narrowing the excitable gap and making it harder for the wavefront to sustain reentry. Its onset is rapid with the IV loading dose, though full tissue saturation takes days.

Deep sedation (propofol, or general anesthesia in severe cases) reduces pain perception and slashes sympathetic outflow. This directly dampens the catecholamine side of the loop.

ICD reprogramming is critical and often overlooked in the acute setting. Lengthening the VT detection interval allows short, self-terminating runs to resolve without a shock. Optimizing antitachycardia pacing (ATP) protocols lets the device painlessly terminate VT by overdrive-pacing the circuit before resorting to a shock. Fewer shocks means less pain, less catecholamine release, and fewer subsequent episodes.

Urgent catheter ablation of the clinical VT circuit is the definitive treatment. If the VT morphology is stable and hemodynamically tolerated, activation mapping can identify the critical isthmus. If the patient is too unstable for prolonged mapping, substrate-based approaches target abnormal electrograms within the scar.

Polymorphic VT looks fundamentally different from monomorphic VT on the monitor. The QRS axis shifts continuously. There is no single stable circuit. The wavefront is chaotic, fragmenting and reforming across the ventricles.

Because there is no single circuit to ablate, treatment depends entirely on identifying the underlying trigger. Four mechanisms account for the vast majority of cases.

Acute ischemia. The most common and most dangerous cause. ST elevation or dynamic ST depression on the 12-lead ECG points to a coronary occlusion or severe demand ischemia. The ischemic border zone creates steep voltage gradients between healthy and injured tissue, setting up multiple small reentrant wavelets. The treatment is reperfusion: emergent catheterization and revascularization. No amount of amiodarone will fix a closed artery.

QT prolongation with Torsades de Pointes. The mechanism is entirely different and we will discuss it in detail below.

Brugada syndrome. Phase 2 reentry in the right ventricular epicardium. A transmural voltage gradient develops during the early repolarization phase because epicardial cells lose their action potential dome while endocardial cells do not. The resulting current flow triggers a closely coupled PVC that degenerates into VF. Fever, certain drugs, and vagal tone are the usual precipitants. Acute management includes isoproterenol (which restores the epicardial action potential dome by augmenting calcium current) and aggressive cooling if febrile.

Catecholaminergic Polymorphic VT (CPVT). A channelopathy of the ryanodine receptor or calsequestrin. Under adrenergic stress, the sarcoplasmic reticulum leaks calcium uncontrollably, producing salvos of delayed afterdepolarizations (DADs). The classic pattern is bidirectional VT (alternating QRS axis) provoked by exercise or emotional stress. Beta-blockers are essential. Flecainide, which directly stabilizes the ryanodine receptor, is additive. Catecholamines are the fuel; removing them is the treatment.

Torsades de Pointes (TdP) is the prototypical polymorphic VT, and it deserves separate treatment because its mechanism, recognition, and management are all distinct.

The name means "twisting of the points." On the rhythm strip, the QRS axis rotates gradually, producing a sinusoidal undulation of the peaks. The complexes appear to twist around the baseline.

The prerequisite is a prolonged QT interval on the baseline ECG. This prolongation may be congenital (Long QT Syndrome) or acquired (drug-induced, hypokalemia, hypomagnesemia). Either way, the prolonged repolarization creates a vulnerable window during which Early Afterdepolarizations (EADs) can emerge. EADs arise during Phase 2 or Phase 3 of the action potential, when L-type calcium channels reactivate in the setting of incomplete repolarization.

TdP has a characteristic initiation sequence: short-long-short. A premature beat is followed by a compensatory pause. The pause lengthens the next action potential even further (because action potential duration is rate-dependent). During that excessively long repolarization, an EAD fires and triggers the arrhythmia. This pause-dependence is the defining feature that separates TdP from other polymorphic VTs.

Treatment addresses each link in this chain.

IV magnesium (2 g bolus) is first-line regardless of the serum magnesium level. Magnesium suppresses EADs by stabilizing calcium channel kinetics. It works within minutes.

Overdrive pacing at 90 to 110 bpm shortens the action potential duration by preventing pauses. When there are no pauses, there are no long action potentials, and EADs lose their foothold. Temporary transvenous pacing is the most reliable method.

Isoproterenol serves as a pharmacological bridge when pacing is not immediately available. By increasing the heart rate, it achieves the same effect: shorter cycle lengths, shorter action potentials, fewer EADs.

The offending drug must be stopped immediately. Potassium should be repleted aggressively to a target of 4.5 to 5.0 mEq/L. Hypokalemia reduces repolarization reserve and amplifies the QT-prolonging effect of any drug.

When standard therapies fail to break the storm, we escalate to direct sympathetic blockade. These are rescue interventions, but they are remarkably effective when the catecholamine-arrhythmia cycle has become self-sustaining.

The stellate ganglion block is the most dramatic. The stellate ganglion sits at the C7-T1 level and provides the majority of cardiac sympathetic innervation. A percutaneous injection of local anesthetic (bupivacaine) into this ganglion eliminates sympathetic input to the heart within minutes. The effect is temporary (hours), but it can break the cycle long enough for other therapies to take hold. In refractory cases, surgical sympathectomy (video-assisted thoracoscopic sympathectomy, or VATS) provides permanent denervation.

Thoracic epidural anesthesia (T1-T4 level) achieves a similar effect through a different route. By blocking the preganglionic sympathetic fibers as they exit the spinal cord, it reduces cardiac sympathetic tone and simultaneously provides profound analgesia. This addresses both the catecholamine drive and the pain component of the loop.

Beta-blocker optimization should happen in parallel. IV esmolol, with its short half-life and titratable infusion, allows precise control of sympathetic blockade. Oral propranolol or nadolol can be started once the acute phase stabilizes. The goal is sustained beta-adrenergic suppression, not a single bolus.